Shots:
- The US FDA has received the 510(k) premarket notification for FreedomEDGE infusion system to subcutaneously administer Phesgo (Perjeta/Herceptin/hyaluronidase-zzxf) in HER2+ breast cancer
- The Infusion System enables efficient large-volume SC drug delivery, addressing unmet needs in oncology infusion centers by improving nurse administration experience while supporting faster, more streamlined clinical workflows
- The system supports SC drugs with varying viscosity, flow rate, & volume requirements, plus shows a 97% adherence rate & has 8 on-label SC drugs used across >30 countries
Ref: Businesswire |  Image: KORU Medical Systems  | Press Release
Related News: StimLabs Reports the US FDA 510(k) Clearance of Theracor for Acute and Chronic Wound Management
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
